publication . Other literature type . Article . 2010

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Michael C. Donohue;
Open Access
  • Published: 01 Sep 2010
  • Publisher: Wiley
free text keywords: Article, Health Policy, Developmental Neuroscience, Epidemiology, Cellular and Molecular Neuroscience, Geriatrics and Gerontology, Psychiatry and Mental health, Clinical Neurology
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue